Up-regulated  ||| S:0 E:13 ||| NNP
14-3-3β  ||| S:13 E:21 ||| NNP
and  ||| S:21 E:25 ||| CC
14-3-3ζ  ||| S:25 E:33 ||| CD
proteins  ||| S:33 E:42 ||| NNS
in  ||| S:42 E:45 ||| IN
prefrontal  ||| S:45 E:56 ||| JJ
cortex  ||| S:56 E:63 ||| NN
of  ||| S:63 E:66 ||| IN
subjects  ||| S:66 E:75 ||| NNS
with  ||| S:75 E:80 ||| IN
schizophrenia ||| S:80 E:93 ||| NN
:  ||| S:93 E:95 ||| :
effect  ||| S:95 E:102 ||| NN
of  ||| S:102 E:105 ||| IN
psychotropic  ||| S:105 E:118 ||| JJ
treatment  ||| S:118 E:128 ||| NN
14-3-3  ||| S:128 E:135 ||| NN
is  ||| S:135 E:138 ||| VBZ
a  ||| S:138 E:140 ||| DT
family  ||| S:140 E:147 ||| NN
of  ||| S:147 E:150 ||| IN
conserved  ||| S:150 E:160 ||| JJ
regulatory  ||| S:160 E:171 ||| JJ
proteins  ||| S:171 E:180 ||| NNS
that  ||| S:180 E:185 ||| IN
bind  ||| S:185 E:190 ||| NN
to  ||| S:190 E:193 ||| TO
a  ||| S:193 E:195 ||| DT
multitude  ||| S:195 E:205 ||| NN
of  ||| S:205 E:208 ||| IN
functionally  ||| S:208 E:221 ||| JJ
diverse  ||| S:221 E:229 ||| JJ
signalling  ||| S:229 E:240 ||| JJ
proteins ||| S:240 E:248 ||| NNS
.  ||| S:248 E:250 ||| .
Various  ||| S:250 E:258 ||| JJ
genetic  ||| S:258 E:266 ||| JJ
studies  ||| S:266 E:274 ||| NNS
and  ||| S:274 E:278 ||| CC
gene  ||| S:278 E:283 ||| NN
expression  ||| S:283 E:294 ||| NN
and  ||| S:294 E:298 ||| CC
proteomic  ||| S:298 E:308 ||| JJ
analyses  ||| S:308 E:317 ||| NNS
have  ||| S:317 E:322 ||| VBP
involved  ||| S:322 E:331 ||| VBN
14-3-3  ||| S:331 E:338 ||| CD
proteins  ||| S:338 E:347 ||| NNS
in  ||| S:347 E:350 ||| IN
schizophrenia  ||| S:350 E:364 ||| NN
( ||| S:364 E:365 ||| -LRB-
SZ ||| S:365 E:367 ||| NNP
) ||| S:367 E:368 ||| -RRB-
.  ||| S:368 E:370 ||| .
On  ||| S:370 E:373 ||| IN
the  ||| S:373 E:377 ||| DT
other  ||| S:377 E:383 ||| JJ
hand ||| S:383 E:387 ||| NN
,  ||| S:387 E:389 ||| ,
studies  ||| S:389 E:397 ||| NNS
about  ||| S:397 E:403 ||| IN
the  ||| S:403 E:407 ||| DT
status  ||| S:407 E:414 ||| NN
of  ||| S:414 E:417 ||| IN
these  ||| S:417 E:423 ||| DT
proteins  ||| S:423 E:432 ||| NNS
in  ||| S:432 E:435 ||| IN
major  ||| S:435 E:441 ||| JJ
depressive  ||| S:441 E:452 ||| JJ
disorder  ||| S:452 E:461 ||| NN
( ||| S:461 E:462 ||| -LRB-
MD ||| S:462 E:464 ||| NNP
)  ||| S:464 E:466 ||| -RRB-
are  ||| S:466 E:470 ||| VBP
still  ||| S:470 E:476 ||| RB
missing ||| S:476 E:483 ||| VBG
.  ||| S:483 E:485 ||| .
Immunoreactivity  ||| S:485 E:502 ||| JJ
values  ||| S:502 E:509 ||| NNS
of  ||| S:509 E:512 ||| IN
cytosolic  ||| S:512 E:522 ||| JJ
14-3-3β  ||| S:522 E:530 ||| NN
and  ||| S:530 E:534 ||| CC
14-3-3ζ  ||| S:534 E:542 ||| CD
proteins  ||| S:542 E:551 ||| NNS
were  ||| S:551 E:556 ||| VBD
evaluated  ||| S:556 E:566 ||| VBN
by  ||| S:566 E:569 ||| IN
Western  ||| S:569 E:577 ||| JJ
blot  ||| S:577 E:582 ||| NN
in  ||| S:582 E:585 ||| IN
prefrontal  ||| S:585 E:596 ||| JJ
cortex  ||| S:596 E:603 ||| NNS
( ||| S:603 E:604 ||| -LRB-
PFC ||| S:604 E:607 ||| NNP
)  ||| S:607 E:609 ||| -RRB-
of  ||| S:609 E:612 ||| IN
subjects  ||| S:612 E:621 ||| NNS
with  ||| S:621 E:626 ||| IN
schizophrenia  ||| S:626 E:640 ||| NN
( ||| S:640 E:641 ||| -LRB-
SZ ||| S:641 E:643 ||| NNP
;  ||| S:643 E:645 ||| :
n=22 ||| S:645 E:649 ||| CD
) ||| S:649 E:650 ||| -RRB-
,  ||| S:650 E:652 ||| ,
subjects  ||| S:652 E:661 ||| NNS
with  ||| S:661 E:666 ||| IN
major  ||| S:666 E:672 ||| JJ
depressive  ||| S:672 E:683 ||| JJ
disorder  ||| S:683 E:692 ||| NN
( ||| S:692 E:693 ||| -LRB-
MD ||| S:693 E:695 ||| NNP
;  ||| S:695 E:697 ||| :
n=21 ||| S:697 E:701 ||| CD
)  ||| S:701 E:703 ||| -RRB-
and  ||| S:703 E:707 ||| CC
age- ||| S:707 E:711 ||| JJ
,  ||| S:711 E:713 ||| ,
gender-  ||| S:713 E:721 ||| JJ
and  ||| S:721 E:725 ||| CC
postmortem  ||| S:725 E:736 ||| JJ
delay-matched  ||| S:736 E:750 ||| JJ
control  ||| S:750 E:758 ||| NN
subjects  ||| S:758 E:767 ||| NNS
( ||| S:767 E:768 ||| -LRB-
n=52 ||| S:768 E:772 ||| NNP
) ||| S:772 E:773 ||| -RRB-
.  ||| S:773 E:775 ||| .
The  ||| S:775 E:779 ||| DT
modulation  ||| S:779 E:790 ||| NN
of  ||| S:790 E:793 ||| IN
14-3-3β  ||| S:793 E:801 ||| NNP
and  ||| S:801 E:805 ||| CC
14-3-3ζ  ||| S:805 E:813 ||| CD
proteins  ||| S:813 E:822 ||| NNS
by  ||| S:822 E:825 ||| IN
psychotropic  ||| S:825 E:838 ||| JJ
medication  ||| S:838 E:849 ||| NN
was  ||| S:849 E:853 ||| VBD
also  ||| S:853 E:858 ||| RB
assessed ||| S:858 E:866 ||| VBN
.  ||| S:866 E:868 ||| .
The  ||| S:868 E:872 ||| DT
analysis  ||| S:872 E:881 ||| NN
of  ||| S:881 E:884 ||| IN
both  ||| S:884 E:889 ||| DT
proteins  ||| S:889 E:898 ||| NNS
in  ||| S:898 E:901 ||| IN
SZ  ||| S:901 E:904 ||| NNP
subjects  ||| S:904 E:913 ||| NNS
with  ||| S:913 E:918 ||| IN
respect  ||| S:918 E:926 ||| NN
to  ||| S:926 E:929 ||| TO
matched  ||| S:929 E:937 ||| VB
control  ||| S:937 E:945 ||| NN
subjects  ||| S:945 E:954 ||| NNS
showed  ||| S:954 E:961 ||| VBD
increased  ||| S:961 E:971 ||| VBN
14-3-3β  ||| S:971 E:979 ||| NNP
( ||| S:979 E:980 ||| -LRB-
Δ=33±10 ||| S:980 E:987 ||| NNP
% ||| S:987 E:988 ||| NN
,  ||| S:988 E:990 ||| ,
p  ||| S:990 E:991 ||| CD
< ||| S:991 E:992 ||| SYM
0.05 ||| S:992 E:996 ||| CD
)  ||| S:996 E:998 ||| -RRB-
and  ||| S:998 E:1002 ||| CC
14-3-3ζ  ||| S:1002 E:1010 ||| NNP
( ||| S:1010 E:1011 ||| -LRB-
Δ=29±6 ||| S:1011 E:1017 ||| NNP
% ||| S:1017 E:1018 ||| NN
,  ||| S:1018 E:1020 ||| ,
p  ||| S:1020 E:1021 ||| CD
< ||| S:1021 E:1022 ||| SYM
0.05 ||| S:1022 E:1026 ||| CD
)  ||| S:1026 E:1028 ||| -RRB-
immunoreactivity  ||| S:1028 E:1045 ||| NN
in  ||| S:1045 E:1048 ||| IN
antipsychotic-free  ||| S:1048 E:1067 ||| JJ
but  ||| S:1067 E:1071 ||| CC
not  ||| S:1071 E:1075 ||| RB
in  ||| S:1075 E:1078 ||| IN
antipsychotic-treated  ||| S:1078 E:1100 ||| NNP
SZ  ||| S:1100 E:1103 ||| NNP
subjects ||| S:1103 E:1111 ||| NNS
.  ||| S:1111 E:1113 ||| .
Immunoreactivity  ||| S:1113 E:1130 ||| JJ
values  ||| S:1130 E:1137 ||| NNS
of  ||| S:1137 E:1140 ||| IN
14-3-3β  ||| S:1140 E:1148 ||| NNP
and  ||| S:1148 E:1152 ||| CC
14-3-3ζ  ||| S:1152 E:1160 ||| NNP
were  ||| S:1160 E:1165 ||| VBD
not  ||| S:1165 E:1169 ||| RB
altered  ||| S:1169 E:1177 ||| VBN
in  ||| S:1177 E:1180 ||| IN
MD  ||| S:1180 E:1183 ||| NNP
subjects ||| S:1183 E:1191 ||| NNS
.  ||| S:1191 E:1193 ||| .
These  ||| S:1193 E:1199 ||| DT
results  ||| S:1199 E:1207 ||| NNS
show  ||| S:1207 E:1212 ||| VBP
the  ||| S:1212 E:1216 ||| DT
specific  ||| S:1216 E:1225 ||| JJ
up-regulation  ||| S:1225 E:1239 ||| NN
of  ||| S:1239 E:1242 ||| IN
14-3-3β  ||| S:1242 E:1250 ||| NNP
and  ||| S:1250 E:1254 ||| CC
14-3-3ζ  ||| S:1254 E:1262 ||| CD
proteins  ||| S:1262 E:1271 ||| NNS
in  ||| S:1271 E:1274 ||| IN
PFC  ||| S:1274 E:1278 ||| NNP
of  ||| S:1278 E:1281 ||| IN
SZ  ||| S:1281 E:1284 ||| NNP
subjects  ||| S:1284 E:1293 ||| NNS
and  ||| S:1293 E:1297 ||| CC
suggest  ||| S:1297 E:1305 ||| VB
a  ||| S:1305 E:1307 ||| DT
possible  ||| S:1307 E:1316 ||| JJ
down-regulation  ||| S:1316 E:1332 ||| NN
of  ||| S:1332 E:1335 ||| IN
both  ||| S:1335 E:1340 ||| DT
proteins  ||| S:1340 E:1349 ||| NNS
by  ||| S:1349 E:1352 ||| IN
antipsychotic  ||| S:1352 E:1366 ||| JJ
treatment ||| S:1366 E:1375 ||| NN
.  ||| S:1375 E:1377 ||| .
